Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.08 | 0.41 | 0.14 |
| FCF Yield | -3.68% | 12.82% | -5.13% | -9.59% |
| EV / EBITDA | 13.03 | -12.43 | -15.94 | -15.89 |
| Quality | ||||
| ROIC | 8.90% | -15.24% | -13.37% | -9.20% |
| Gross Margin | 100.00% | 94.81% | 95.10% | 83.29% |
| Cash Conversion Ratio | -0.47 | -1.23 | 0.62 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.79% | 176.91% | 283.20% | 1,174.72% |
| Free Cash Flow Growth | -127.35% | 345.21% | 47.46% | -509.25% |
| Safety | ||||
| Net Debt / EBITDA | 1.40 | -1.91 | -1.51 | -1.89 |
| Interest Coverage | 8.60 | -14.06 | -10.91 | -11.43 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 18.50 | -156.42 | -137.88 | -37.97 |